Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Research & Development (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Research & Development for 5 consecutive years, with $11.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 57.6% to $11.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $79.1 million, a 6.39% decrease, with the full-year FY2025 number at $61.1 million, down 27.65% from a year prior.
  • Research & Development was $11.3 million for Q4 2025 at Lexicon Pharmaceuticals, down from $15.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $26.7 million in Q4 2024 to a low of $11.3 million in Q4 2025.
  • A 3-year average of $17.0 million and a median of $15.0 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 80.77% in 2024, then plummeted 57.6% in 2025.
  • Lexicon Pharmaceuticals' Research & Development stood at $14.8 million in 2023, then soared by 80.77% to $26.7 million in 2024, then tumbled by 57.6% to $11.3 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Research & Development are $11.3 million (Q4 2025), $15.3 million (Q1 2025), and $26.7 million (Q4 2024).